{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:55:40Z","timestamp":1759334140089,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.lungcan.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T11:17:22Z","timestamp":1673090242000},"page":"98-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study"],"prefix":"10.1016","volume":"176","author":[{"given":"Fabio","family":"Conforti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Vivanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Catania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Maiettini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Varano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Di Venosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piermario","family":"Salvini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelmira","family":"Ballatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso Martino","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.01.004_b0005","doi-asserted-by":"crossref","first-page":"102014","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: From biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.004_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.004_b0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.01.004_b0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2023.01.004_b0025","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2023.01.004_b0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.lungcan.2023.01.004_b0035","first-page":"S1342","article-title":"LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial. Annals of","volume":"32","author":"Girard","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.lungcan.2023.01.004_b0040","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2","article-title":"Combined Etoposide, Ifosfamide, and Cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma","volume":"91","author":"Loehrer","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.004_b0045","first-page":"893","article-title":"Ifosfamide, and Cisplatin in the Treatment of Patients with Advanced Thymoma and Thymic Carcinoma. A French Experience","volume":"5","author":"Grassin","year":"2010","journal-title":"JTO"},{"key":"10.1016\/j.lungcan.2023.01.004_b0050","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatement of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2023.01.004_b0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ctrv.2018.10.001","article-title":"Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)","volume":"71","author":"Imbimbo","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"9","key":"10.1016\/j.lungcan.2023.01.004_b0060","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.01.004_b0065","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2023.01.004_b0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2023.01.004_b0075","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. May 28, 2009. https:\/\/evs. nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf."},{"issue":"7","key":"10.1016\/j.lungcan.2023.01.004_b0080","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.1995.13.7.1600","article-title":"High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas","volume":"13","author":"Le Cesne","year":"1995","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.01.004_b0085","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","article-title":"High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies dose\u2013response and schedule dependence","volume":"15","author":"Patel","year":"1997","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.01.004_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/2045-3329-4-16","article-title":"High-dose continuous-infusion ifosfamide in advanced well-differentiated\/dedifferentiated liposarcoma","volume":"4","author":"Sanfilippo","year":"2014","journal-title":"Clin Sarcoma Res."},{"issue":"19","key":"10.1016\/j.lungcan.2023.01.004_b0095","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.01.004_b0100","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.esmoop.2021.100188","article-title":"Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)","volume":"6","author":"Conforti","year":"2021","journal-title":"ESMO Open."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:03:30Z","timestamp":1759237410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":20,"alternative-id":["S0169500223000089"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.004","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}